Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular - Top-Institutions - MDSpire

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular

  • By

  • Steven E. Nissen

  • Kathy Wolski

  • David D’Alessio

  • Govinda Weerakkody

  • Jacek Kiljanski

  • Russell J. Wiese

  • Imre Pavo

  • Bertrand Cariou

  • Stephen J. Nicholls

  • June 1, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Endocrinology

  • #2

    Monash University
    Monash University

    Melbourne, Victoria

    Key Differentiators

    • Endocrinology

  • #3

    Allegheny General Hospital
    Allegheny General Hospital

    Pittsburgh, Pennsylvania

    Key Differentiators

    • Endocrinology

Original Source(s)

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular

  • by Steven E. Nissen, Kathy Wolski, David D’Alessio, Govinda Weerakkody, Jacek Kiljanski, Russell J. Wiese, Imre Pavo, Bertrand Cariou, Stephen J. Nicholls

  • June 1, 2026

Related Content

Implantation of cardiac resynchronization therapy defibrillator with left bundle branch pacing in a patient with mirror-image dextrocardia: a case report

Soluble fms-like tyrosine kinase-1 and peripartum cardiomyopathy: an exploratory meta-analysis of association and diagnostic performance

Anticoagulation in Device-Detected Atrial Fibrillation—Uncertainty and Heterogeneity in Value